The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy’s Cancer Centre
Beth Russell(King's College London), Saoirse Dolly(Guy's and St Thomas' NHS Foundation Trust), Daniel Smith(Guy's and St Thomas' NHS Foundation Trust), Mieke Van Hemelrijck(Ghent University Hospital), Deborah Enting(Guy's and St Thomas' NHS Foundation Trust), Charalampos Gousis(Guy's and St Thomas' NHS Foundation Trust), Vishal Manik(Tata Memorial Hospital), Vasiliki Michalarea(Royal Marsden Hospital), Sophie Papa(Guy's Hospital), Christina Karampera(Guy's and St Thomas' NHS Foundation Trust), Anne Rigg(National Health Service), Kasia Owczarczyk(King's College London), Jose Roca(Guy's and St Thomas' NHS Foundation Trust), James Spicer(King's College London), Angela Swampillai(Guy's and St Thomas' NHS Foundation Trust), Ailsa Sita-Lumsden(Guy's and St Thomas' NHS Foundation Trust), B. Michael Dann(Guy's and St Thomas' NHS Foundation Trust), Hartmut Kristeleit(Guy's and St Thomas' NHS Foundation Trust), Mary Lei(Guy's and St Thomas' NHS Foundation Trust), Debra H. Josephs(Guy's and St Thomas' NHS Foundation Trust), Harriet Wylie(King's College London), Nisha Shaunak(Guy's and St Thomas' NHS Foundation Trust), Lucy Flanders(Guy's and St Thomas' NHS Foundation Trust), Charlotte Moss(Southampton General Hospital), Elinor J. Sawyer(King's College London), Eirini Tsotra(Guy's and St Thomas' NHS Foundation Trust), Vikash Jogia(Guy's and St Thomas' NHS Foundation Trust), Paul J. Ross(King's College Hospital NHS Foundation Trust), Rebecca Kristeleit(Guy's and St Thomas' NHS Foundation Trust), Muhammad Khan(Guy's and St Thomas' NHS Foundation Trust), Ana Montes(Guy's and St Thomas' NHS Foundation Trust), Kamarul Zaki(Guy's and St Thomas' NHS Foundation Trust), Anna Haire(King's College London), Anca Mera(Guy's and St Thomas' NHS Foundation Trust), Irene De Francesco(Guy's Hospital)
Cited by 4
Related Papers
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
|The Lancet Oncology|2019|1.2k
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
|The Lancet Oncology|2021|614
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
|The Lancet Oncology|2021|401
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374
Prevalence and demography of transsexualism in Belgium
|European Psychiatry|2007|306